FDA Approved: TABRECTA

The first FDA-approved treatment that specifically targets metastatic non-small cell lung cancer (mNSCLC) with a mutation that leads to MET exon 14 skipping (METex14).

Important Safety Information

TABRECTA™ (capmatinib) tablets may cause serious side effects. Tell your health care provider right away if you get any of the following:

  • Lung or breathing problems. TABRECTA may cause infla...

See More
Approved Use

TABRECTA is a prescription medicine used to treat adults with a kind of lung cancer called non-small cell lung cancer (NSCLC) that:

  • has spread to other parts of the body or cannot be removed by surgery (metastatic), and
  • whose tumors have an abnormal mesenchymal-epithelial transitio...
See More
TESTING AND DIAGNOSIS

Biomarker testing matters

Comprehensive testing can lead to a targeted treatment.

SEE HOW
HOW TABRECTA MAY HELP

Treatment with TABRECTA

Discover proven results from the clinical trial.

SEE RESULTS